Joining the SWPDC portfolio means we’re aligned with a group that provides meaningful support to innovators, including connections across clinical, regulatory, and reimbursement networks.
We clearly see the impact SalivIQ will have on the pediatric population as we bring non-invasive, saliva-based testing for strep throat to the point of care. We look forward to collaborating with the SWPDC team and interacting closely with pediatric practices as we advance our patient-centered solution.
Pediatric Consortium
We’re pleased to share that SalivIQ is now a portfolio company with the SWPDC – Southwest National Pediatric Device Innovation Consortium – an FDA-funded consortium aimed at advancing pediatric medical device innovation.
Joining the SWPDC portfolio means we’re aligned with a group that provides meaningful support to innovators, including connections across clinical, regulatory, and reimbursement networks.
We clearly see the impact SalivIQ will have on the pediatric population as we bring non-invasive, saliva-based testing for strep throat to the point of care. We look forward to collaborating with the SWPDC team and interacting closely with pediatric practices as we advance our patient-centered solution.
Archives
Categories
Categories
Recent Posts
Pediatric Consortium
January 29, 2026Lead Investor Secured
January 25, 2026SalivIQ Featured
October 23, 2025Tags
Meta
Calendar